NUCLIDIUM AG is a clinical-stage radiopharmaceutical company pioneering next-generation copper-based radiotheranostics that enable the direct conversion from cancer diagnosis to treatment. Leveraging copper isotopes, Copper-61 for diagnostics and Copper-67 for therapeutics, the company has built a pipeline of candidates for oncology and women's health.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €26 M | May, 2026 | series-b |
Industries
Frequently Asked Questions
Where is NUCLIDIUM AG located?
NUCLIDIUM AG is located in Basel, Switzerland.
What industries does NUCLIDIUM AG operate in?
NUCLIDIUM AG operates in the following industries: radiopharmaceuticals, biotechnology, oncology.
How much total funding has NUCLIDIUM AG raised?
NUCLIDIUM AG has raised a total of $26,000,000.
Who are the investors in NUCLIDIUM AG?
The investors in NUCLIDIUM AG are: Kurma Growth Opportunities Fund, Angelini Ventures, EIB co-investment facility Aurea, Wellington Partners, Neva SGR (Intesa Sanpaolo Group), DeepTech & Climate Fonds (DTCF), Bayern Kapital, Vives Partners, NRW.BANK.
What is NUCLIDIUM AG?
NUCLIDIUM AG is a clinical-stage biotechnology company that focuses on developing next-generation copper-based radiopharmaceuticals for the diagnosis and treatment of cancer.
What technology does NUCLIDIUM AG use?
NUCLIDIUM AG utilizes its proprietary CuTrace platform, which combines tumor-targeting molecules with copper isotopes, specifically Copper-61 for diagnostics and Copper-67 for therapeutics.
Where are the headquarters of NUCLIDIUM AG located?
NUCLIDIUM AG is based in Basel, Switzerland, and also maintains operations as Nuclidium (DE) GmbH in Munich, Germany.
What is the main goal of the pipeline at NUCLIDIUM AG?
The goal of the NUCLIDIUM AG pipeline is to overcome existing limitations in radiotheranostics by providing scalable, accessible, and clinically superior theranostic solutions for various oncology indications, including prostate and breast cancer.